STAT3 and breast carcinoma: In HER-positive breast cancer patients, affecting the IL-6/JAK2/STAT3 axis by trastuzumab therapy alone or in combination with ruxolitinib, a selective JAK1/2 inhibitor, significantly improves clinical outcomes, as reported by Rodriguez-Barrueco et al. [56].